InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Recent Access of Manufacturing Technologies Now Give It the Potential to Synthetically Produce Rare Cannabinoids at Large Scale, a Unique and Coveted Position in the Rapidly Developing Rare Cannabinoid Space
Rare cannabinoids are cannabinoid compounds other than CBD and THC which are not yet produced in large scale but which have potentially greater benefits InMed acquired BayMedica in October 2021, bringing on board unmatched expertise in large-scale bio-production technologies applicable to rare cannabinoids As a result of this acquisition, InMed, already a leader in the production of rare cannabinoid CBC, is now in the unique and highly desired position to undertake large-scale production of other rare cannabinoids, with applications as wide as the current CBD market The company plans to launch new rare cannabinoid products in the first half of…
